Study of Immune Checkpoint Inhibitor-Related Hepatitis in Cancer Patients Observing Liver Injury Patterns and Treatment Responses

What this Trial Is About

This research focuses on liver injury caused by immune checkpoint inhibitors ICIs, a cancer treatment that helps the immune system fight tumors. Although ICIs are effective, they can lead to immune-related side effects such as liver inflammation known as ICI-induced hepatitis or CHILI. The study aims to understand CHILIs clinical patterns, treatment responses, and risks of recurrence, particularly examining different types of liver injury to improve treatment decisions. Participants are adult cancer patients who have received at least one ICI injection and developed hepatitis with specific liver enzyme elevations or severe hepatitis symptoms. The study observes patients treated with ICIs alone or in combination with other cancer therapies. Blood samples are collected to monitor liver injury types and progression over time, following real-world treatment approaches as guided by international recommendations or pragmatic care when no consensus exists. During the study, participants will have their liver injury type ratios measured at multiple time points up to 12 months. Data collection includes blood tests and clinical evaluations to track treatment effects and liver inflammation. The study will provide insights into managing ICI-related liver toxicity, with involvement lasting up to 12 months or longer depending on follow-up needs.

Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis